This dual effect—enhancing IRS signaling while reducing JAK2-mediated inflammation—suggests that GP may effectively activate the INSR–IRS2–Akt signaling axis, ultimately improving insulin sensitivity and mitigating insulin resistance. The gene discussed is INSR; the disease is Insulin resistance.